Alcon ALC
Alcon is a global medical devices company specializing in eye care, developing and marketing products and equipment for cataract, retina, and refractive surgery, as well as contact lenses and eye care solutions. Alcon shows solid financial health (score 6.91) with moderate leverage (ND/EBITDA 1.60) and revenue growth of 8.70%, but its current valuation (P/E 49.21) is demanding and its return on equity is weak (ROE 2.94).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Alcon is a global medical devices company specializing in eye care, developing and marketing products and equipment for cataract, retina, and refractive surgery, as well as contact lenses and eye care solutions. Alcon shows solid financial health (score 6.91) with moderate leverage (ND/EBITDA 1.60) and revenue growth of 8.70%, but its current valuation (P/E 49.21) is demanding and its return on equity is weak (ROE 2.94).
Score by category
| Category | Score |
|---|---|
| Financial health | 6.9 |
| Quality / Moat | 4.8 |
| Valuation | 4.9 |
| Growth | 6.5 |
| Dividend | 4.6 |
| Momentum | 4.1 |
| Risk & Context | 7.4 |
OVERALL SCORE: 5.6/10
Context and risks
Alcon is a Swiss company with solid governance, but the inherent regulatory risk of the medical devices sector (quality controls, labeling) is present. Exposure to emerging markets with volatile currencies adds minor risk.
News considered in the analysis
- Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure — Artículo de análisis que señala presión sobre los beneficios, pero es una opinión de un portal, no un hecho material nuevo.
- Bernstein unveils top European medtech stock picks to buy for H2 — Recomendación de compra de un bróker de prestigio; puede dar soporte a corto plazo, pero no es un evento fundamental.
- STAAR Surgical hires former CEO to lead commercial team — Noticia sobre un competidor directo; no tiene un impacto directo en los fundamentales de Alcon.
- Bill Ackman bets AI will make this old-school business stronger — Comentario genérico sobre una apuesta de un inversor famoso; no aporta información específica sobre Alcon.
- Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap — Análisis sobre un competidor (Cooper), no sobre Alcon; sin impacto directo.
Verdict: Hold; the company has solid fundamentals, but the valuation does not offer an attractive margin of safety in the short term.
Main risk: Regulatory and pricing pressure in the medical devices sector, along with a demanding valuation (P/E 49.21), are the main risks for Alcon.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →